Biomedical Engineering Reference
In-Depth Information
Figure 4.4
HER-2 as a predictive biomarker for trastuzumab. A. Progression-
free survival (left) and overall survival (right) for patients with HER-
2-amplified metastatic breast cancer treated with chemotherapy
+/- trastuzumab. Reproduced with permission from Slamon
et al.
[78]. B. Disease-free survival (left) and overall survival (right) for
patients with early-stage HER-2 positive breast cancer treated with
chemotherapy +/- trastuzumab. Reproduced with permission from
Romond
. [82]. C. HER-2 amplification predicts the response
to trastuzumab. Patients with metastatic cancer were treated with
chemotherapy +/- trastuzumab. Overall survival for patients with
HER-2 amplified tumors are shown on the right and with HER-2
non-amplified tumors are shown on the left. Reproduced with
permission from Mass
et al
et al
. [87].
